Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26021786 | 0.82 | NOTUM (0.58) | NOTUMCTSSSRD5A1KMT2AMEN1 | |
| SCHEMBL26021798 | 0.82 | NOTUM (0.41) | NOTUMSRD5A1AADAT | |
| SCHEMBL11927508 | 0.79 | NOTUM (0.56) | NOTUMCTSSOPRM1OPRK1OPRL1 | |
| SCHEMBL23055860 | 0.77 | GAA (0.50) | NOTUMKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL17529308 | 0.73 | NOTUM (0.42) | NOTUMOPRM1OPRK1OPRL1CHRNB4 | |
| SCHEMBL23055514 | 0.72 | KMT2A (0.48) | NOTUMKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL10062782 | 0.72 | OPRM1 (0.47) | NOTUMCTSSOPRM1OPRK1OPRL1 | |
| SCHEMBL7678990 | 0.70 | AADAT (0.55) | NOTUMSRD5A1KMT2AMEN1MAPT | |
| SCHEMBL2364079 | 0.70 | KMT2A (0.45) | NOTUMSRD5A1KMT2AMEN1MAPT | |
| SCHEMBL26684629 | 0.70 | KMT2A (0.46) | NOTUMSRD5A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | NOTUM 2955/4885CTSS 1238/4885SRD5A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.